默沙东应该急了。4月24日,默沙东公布2025 Q1业绩,总体营收小幅下锉,主要原因是两大支柱产品全球药王K药和HPV疫苗佳达修(Gardasil/Gardasil 9)都未及销售预期。另外两个数字则惨烈得多——佳达修Q1销售额仅为13.27亿美元,同比大幅下滑41%;其中,默沙东中国区收入同比下滑62%至6.68亿美元,在默沙东全球的业务份额降至不足5%,跌幅远超公司平均水平。默沙东2025Q1...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.